Cargando…
A PVDF Receiver for Acoustic Monitoring of Microbubble-Mediated Ultrasound Brain Therapy
The real-time monitoring of spectral characteristics of microbubble (MB) acoustic emissions permits the prediction of increases in blood–brain barrier (BBB) permeability and of tissue damage in MB-mediated focused ultrasound (FUS) brain therapy. Single-element passive cavitation detectors provide li...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9921684/ https://www.ncbi.nlm.nih.gov/pubmed/36772406 http://dx.doi.org/10.3390/s23031369 |
Sumario: | The real-time monitoring of spectral characteristics of microbubble (MB) acoustic emissions permits the prediction of increases in blood–brain barrier (BBB) permeability and of tissue damage in MB-mediated focused ultrasound (FUS) brain therapy. Single-element passive cavitation detectors provide limited spatial information regarding MB activity, greatly affecting the performance of acoustic control. However, an array of receivers can be used to spatially map cavitation events and thus improve treatment control. The spectral content of the acoustic emissions provides additional information that can be correlated with the bio-effects, and wideband receivers can thus provide the most complete spectral information. Here, we develop a miniature polyvinylidene fluoride (PVDF thickness = 110 μm, active area = 1.2 mm(2)) broadband receiver for the acoustic monitoring of MBs. The receiver has superior sensitivity (2.36–3.87 V/MPa) to those of a commercial fibre-optic hydrophone in the low megahertz frequency range (0.51–5.4 MHz). The receiver also has a wide −6 dB acceptance angle (54 degrees at 1.1 MHz and 13 degrees at 5.4 MHz) and the ability to detect subharmonic and higher harmonic MB emissions in phantoms. The overall acoustic performance of this low-cost receiver indicates its suitability for the eventual use within an array for MB monitoring and mapping in preclinical studies. |
---|